News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
140,487 Results
Type
Article (4416)
Company Profile (66)
Press Release (136002)
Multimedia
Podcasts (5)
Webinars (7)
Section
Business (47328)
Career Advice (209)
Deals (6169)
Drug Delivery (17)
Drug Development (17448)
Employer Resources (18)
FDA (1507)
Job Trends (2797)
News (66284)
Policy (3664)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (313)
Accelerated approval (13)
ADA (15)
Adcomms (1)
Allergies (51)
Alliances (11497)
ALS (73)
Alzheimer's disease (518)
Antibody-drug conjugate (ADC) (177)
Approvals (1644)
Artificial intelligence (153)
ASCO (72)
Autoimmune disease (157)
Automation (17)
Bankruptcy (38)
Best Places to Work (2252)
BIO (51)
BIOSECURE Act (14)
Biosimilars (36)
Biotechnology (62)
Bladder cancer (69)
Brain cancer (16)
Breast cancer (237)
Cancer (1801)
Cardiovascular disease (68)
Career advice (202)
Career pathing (5)
CAR-T (168)
CDC (2)
Celiac Disease (1)
Cell therapy (428)
Cervical cancer (11)
Clinical research (16182)
Collaboration (753)
Compensation (403)
Complete response letters (10)
COVID-19 (452)
CRISPR (30)
C-suite (559)
Cystic fibrosis (49)
Data (2791)
Depression (31)
Dermatology (18)
Diabetes (153)
Diagnostics (802)
Digital health (3)
Diversity, equity & inclusion (8)
Drug discovery (142)
Drug pricing (10)
Drug shortages (3)
Duchenne muscular dystrophy (73)
Earnings (13904)
Editorial (8)
Employer resources (19)
Events (27429)
Executive appointments (452)
FDA (2447)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (8)
Frontotemporal dementia (20)
Funding (634)
Gene editing (71)
Generative AI (18)
Gene therapy (236)
GLP-1 (196)
Government (377)
Guidances (74)
Healthcare (1609)
Hematology (57)
HIV (15)
Huntington's disease (20)
IgA nephropathy (52)
Immunology and inflammation (83)
Immuno-oncology (32)
Indications (48)
Infectious disease (532)
Inflammatory bowel disease (89)
Inflation Reduction Act (1)
Influenza (46)
Intellectual property (96)
Interviews (18)
IPO (2980)
IRA (4)
Job creations (671)
Job search strategy (184)
JPM (3)
Kidney cancer (3)
Labor market (18)
Layoffs (42)
Leadership (3)
Legal (642)
Liver cancer (18)
Longevity (13)
Lung cancer (189)
Lymphoma (174)
Machine learning (20)
Management (5)
Manufacturing (361)
Marketing (2)
MASH (25)
Medical device (412)
Medtech (419)
Mergers & acquisitions (3619)
Metabolic disorders (330)
mRNA (46)
Multiple sclerosis (74)
NASH (1)
Neurodegenerative disease (142)
Neuropsychiatric disorders (17)
Neuroscience (993)
Neurotech (1)
NextGen: Class of 2026 (861)
Non-profit (282)
Now hiring (7)
Obesity (146)
Opinion (49)
Ovarian cancer (96)
Pain (60)
Pancreatic cancer (106)
Parkinson's disease (161)
Partnered (6)
Patents (179)
Patient recruitment (257)
Peanut (20)
People (17623)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase 1 (6409)
Phase 2 (7775)
Phase 3 (3983)
Pipeline (2894)
Policy (39)
Postmarket research (210)
Preclinical (2774)
Press Release (51)
Prostate cancer (71)
Psychedelics (5)
Radiopharmaceuticals (64)
Rare diseases (263)
Real estate (1465)
Recruiting (10)
Regulatory (3807)
Reports (16)
Research institute (316)
Resumes & cover letters (20)
Rett syndrome (22)
RNA editing (6)
RSV (15)
Schizophrenia (19)
Series A (127)
Series B (89)
Service/supplier (2)
Sickle cell disease (31)
Special edition (3)
Spinal muscular atrophy (44)
Sponsored (6)
Startups (1001)
State (1)
Stomach cancer (2)
Supply chain (28)
Tariffs (10)
The Weekly (5)
Vaccines (168)
Venture capital (28)
Weight loss (59)
Women's health (17)
Worklife (2)
Date
Today (30)
Last 7 days (137)
Last 30 days (619)
Last 365 days (8824)
2026 (4885)
2025 (8536)
2024 (9123)
2023 (9883)
2022 (12000)
2021 (12645)
2020 (9851)
2019 (6679)
2018 (5275)
2017 (6073)
2016 (5593)
2015 (6439)
2014 (4924)
2013 (4060)
2012 (4397)
2011 (4870)
2010 (4514)
Location
Africa (145)
Alabama (60)
Alaska (1)
Arizona (41)
Arkansas (3)
Asia (9190)
Australia (2134)
California (4588)
Canada (1103)
China (421)
Colorado (95)
Connecticut (152)
Delaware (71)
Europe (20148)
Florida (528)
Georgia (71)
Hawaii (2)
Idaho (11)
Illinois (228)
India (30)
Indiana (251)
Iowa (5)
Japan (133)
Kansas (15)
Kentucky (5)
Louisiana (4)
Maine (2)
Maryland (487)
Massachusetts (3573)
Michigan (109)
Minnesota (201)
Mississippi (1)
Missouri (16)
Montana (12)
Nebraska (2)
Nevada (38)
New Hampshire (8)
New Jersey (830)
New Mexico (6)
New York (1056)
North Carolina (533)
North Dakota (5)
Northern California (2353)
Ohio (87)
Oklahoma (7)
Oregon (7)
Pennsylvania (780)
Puerto Rico (13)
Rhode Island (6)
South America (203)
South Carolina (7)
Southern California (1823)
Tennessee (31)
Texas (641)
United States (14563)
Utah (44)
Vermont (1)
Virginia (35)
Washington D.C. (9)
Washington State (605)
West Virginia (1)
Wisconsin (27)
140,487 Results for "sqz biotechnologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)
The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of SQZ Biotechnologies Company — ticker symbol SQZ — from the NYSE.
July 3, 2023
·
1 min read
Business
SQZ Biotechnologies Provides Update on Collaboration with Roche
SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
July 25, 2023
·
4 min read
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company —a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them rather than using electricity.
February 29, 2024
·
3 min read
Business
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates.
November 8, 2023
·
6 min read
Genetown
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023.
November 3, 2023
·
4 min read
Business
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, reported second quarter 2023 financial results and recent portfolio updates.
August 10, 2023
·
6 min read
Business
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.
March 22, 2023
·
7 min read
Business
Roche Decides Not to Exercise Solid Tumor Option with SQZ
Embattled SQZ Biotechnologies announced Tuesday that the Swiss biotech will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
July 25, 2023
·
2 min read
·
Connor Lynch
Drug Development
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial.
March 22, 2023
·
7 min read
Business
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, reported first quarter 2023 financial results and recent portfolio updates.
May 10, 2023
·
6 min read
1 of 14,049
Next
